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  In this systematic review article, we aim to summarize the most up-to-date evidence regarding elevations of 
cardiac troponin, especially in clinical scenarios other than obstructive coronary artery disease. The accurate 
interpretation of raised cardiac troponin is challenging because it relies on unconfirmed postulations and dog-
matic knowledge (e.g., the exclusive provenience of cardiac troponin from cardiac myocytes), based on which 
every troponin elevation is assumed to definitely indicate myocardial damage. Indeed, the investigation of the 
pathophysiologic mechanism leading to the release in the bloodstream of cardiac biomarkers should be the 
first step of the diagnostic process to fully understand the clinical significance of the elevated serum levels 
and identify the best management. A prominent effort should be put in place to identify the contribution of 
potential confounding factors, both cardiac and non-cardiac in etiology, with the ability to affect synthesis and 
clearance of cardiac biomarkers. Regardless of the underlying cause, it is well established that cardiovascu-
lar biomarkers are increasingly useful to further risk stratification and prognosticate patients. Accordingly, we 
sought to clarify the meaning and impact of elevated cardiac troponin in those frequently encountered real-
world scenarios presenting clinicians with a diagnostic dilemma, with the final goal of facilitating the diagno-
sis and help optimize individually tailored treatment strategies.
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Background
Since the landmark discovery of the utility of serum biomark-
ers in diagnosing myocardial necrosis more than a half century 
ago [1], numerous advances and evolving concepts in macro-
molecular biomarkers have emerged. Approximately 40 years 
ago, the International Society and Federation of Cardiology 
and World Health Organization (WHO) defined the initial di-
agnostic criteria for ischemic heart disease [2]. Subsequently, 
it was recognized by expert consensus opinion that acute 
myocardial infarction (MI) can be detected by utilization of 
pertinent clinical history, electrocardiographic (ECG) findings, 
and highly sensitive biochemical markers for myocardial inju-
ry [3]. With the advent of more accurate cardiovascular bio-
markers, the term myocardial infarction was updated with a 
more precise and meaningful definition to assist in immediate 
treatment directives: revascularization and reperfusion strat-
egies. In 2018, a joint taskforce of the European Society of 
Cardiology/American College of Cardiology Federation/American 
Heart Association/World Heart Federation revised the defini-
tion of MI as myocardial necrosis secondary to ischemia [4]. 
It is now a standard practice to first categorize MI, based on 
ECG findings, as ST-segment elevation myocardial infarction 
(STEMI) versus non-ST-segment elevation myocardial infarc-
tion (NSTEMI), and then further distinguish MI into 5 groups 
based on clinical, pathological, and prognostic variations, as 
well as treatment dictums (Table 1). Acute coronary syndrome 
(ACS) includes unstable angina, NSTEMI, and STEMI; it is a con-
tinuum of myocardial ischemia due to an abrupt decrease of 
oxygen-rich blood flow through the coronary arteries [4]. The 
measurement of serum cardiac troponin (cTn) levels has be-
come the criterion standard biomarker in diagnosing myocar-
dial ischemia and infarction [5,6]. Indeed, as cardio-specific 
contractile proteins, cardiac troponin T (cTnT) and I (cTnI) have 
been shown to be superior to creatine kinase MB (CK-MB) in 
the detection of myocardial injury, especially in instances of 
minor damage, due to their high sensitivity and favorable ki-
netics (Tables 2–4) [7,8].
Conventionally, the term myocardial injury is used in a broad 
fashion to describe a disorder in which cardiac troponin is el-
evated in the serum, with at least 1 value above the 99th per-
centile upper reference limit (URL). Such injury is classified as 
acute if characterized by a rise and/or fall in cardiac troponin 
values (Figure 1). Elevated cardiac troponin can also be ob-
served in the absence of acute myocardial ischemia or obstruc-
tive CAD in a host of clinical conditions (reviewed in Table 5), 
confirming that cardiac biomarkers are specific for the heart 
but not for ACS.
Slight elevations in serum cTn often lead to extensive and 
costly cardiovascular workups, which may sidetrack clinicians, 
leading them astray from the true cause of cTn elevation. The 
present article reviews a) the pathophysiology of cTn release 
Type 1: Spontaneous MI
Related to atherosclerotic plaque rupture, ulceration, fissuring, erosion, or dissection leading to intraluminal thrombus in one or 
more coronary arteries leading to ischemia and resultant myocyte necrosis
Type 2: MI secondary to oxygen supply and demand mismatch/ischemia imbalance
Ischemia imbalance leading to myocyte necrosis and is resultant from a condition other than CAD
Type 3: MI secondary to sudden cardiac death (biomarker values unavailable)
Cardiac death associated with symptoms and ECG findings suggestive of ischemia in the absence of cardiac biomarkers
Type 4a: MI secondary to percutaneous coronary intervention (PCI)
PCI-associated MI defined arbitrarily as an elevation in cTn >5×99th percentile of the upper limit of normal with normal baseline 
values or a rise of cTn values >20% of previously elevated baseline values that are stable or falling in association with the 
presence of at least one of the following: symptoms suggestive of cardiac ischemia, new ischemic ECG findings or new LBBB, 
angiographic loss of patency of a major coronary vessel or a side branch or persistent slow- or no-flow or embolization, or 
imaging demonstrating new loss of viable myocardium or new regional wall motion abnormality
Type 4b: MI secondary to stent thrombosis
MI associated with stent thrombosis as detected by coronary angiography or autopsy with a combination of myocardial ischemia 
and rise and/or fall of cardiac biomarkers with at least one value ³99th percentile of the upper limit of normal
Type 5: MI secondary to coronary artery bypass grafting (CABG)
MI associated with CABG defined arbitrarily as an elevation in cardiac biomarker levels >10×99th percentile of the upper limit 
of normal in patients with normal baseline values in addition to at least one of the following: new pathological Q waves or 
new LBBB, new graft or new native coronary artery occlusion, or imaging demonstrating new loss of viable myocardium or new 
regional wall motion abnormality
Table 1. Classification of myocardial infarction [4].
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from the heart and different organs, and b) the clinical sce-
narios leading to cTn elevations, with a special focus on those 
unrelated to obstructive coronary artery disease.
Physiology of cardiac troponin
Troponins are integral regulatory proteins located on the thin 
actin filament within the myocytes of striated heart muscle, 
and are released when cardiac myocyte injury occurs. These 
proteins are responsible for the intricate contraction-relaxation 
cycle of myocytes (Figure 2). The cTn complex is composed of 3 
different subunits: cardiac troponin-C (cTnC, the calcium-bind-
ing component), cTnT (the tropomyosin-binding component), 
and cTnI (the inhibitory-activity regulator of the myosin-bind-
ing sites on actin thin filaments) [9]. During depolarization of 
the cardiac myocyte, calcium enters the sarcoplasm, binds to 
cTnC, and induces structural changes in the cTn complex. The 
resulting shift of tropomyosin away from the active site of actin 
allows the myosin heads of the thick filament to interact with 
the now-exposed myosin-binding site of the actin filaments, 
thereby producing contraction of the sarcomere and, conse-
quently, the myocardium as a syncytium [9,10]. The existence 
•  High concentration in the heart muscle
•  Absence from other non-cardiac tissue
•  Rapid release into the blood following myocardial injury
•  High sensitivity and specificity in laboratory serum samples
•  Favorable kinetics for detection of myocardial damage and acute coronary syndrome in the hours or days when patients seek 
medical attention
•  Correlation between cardiac biomarker and extent of myocardial injury and prognosis
•  Wide-spread assay availability that are simple, automated, and rapid
•  Well-defined role in diagnosis and management based on medical peer-reviewed literature and clinical trials
Table 2. Features of an “ideal” serum cardiac biomarker [5,6].
Modern markers in use Cardiac Troponin T
Cardiac Troponin I
CK and CK-MB with relative index
Point-of-care Troponin I, CK-MB and myoglobin panel
Obsolete markers Aspartate transaminase
Lactate dehydrogenase





Table 3. Overview of molecular biomarkers of myocardial injury [7,8].
Marker Onset Peak Return to baseline
Troponin T 4–9 h 12–24 h 7–14 d
Troponin I 4–9 h 12–24 h 7–14 d
CK/CK-MB 4–9 h 24 h 2–3 d
Myoglobin 1 h 4–12 h 24 h
Table 4. Comparison of cardiac biomarker kinetics during myocardial injury [5–8].
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Figure 1.  Various clinical scenarios causing an elevation in 
cardiac troponins.
Primary Myocardial Ischemia Plaque rupture
Intraluminal formation of coronary artery thrombus
Supply-Demand Mismatch/Imbalance 
Leading To/Associated with Myocardial 
Ischemia
Coronary vasospasm
Coronary embolism or vasculitis
Coronary endothelial (microvascular) dysfunction without obstructive 
(significant) CAD
Hypertension with and without left ventricular hypertrophy
Hypertrophic cardiomyopathy
Cardiogenic, hypovolemic, or septic shock
Aortic dissection




Cardiac-related in the Absence of CAD Cardiac contusion
Cardiac procedure such as ablation, pacing, or defibrillator shocks
Cardiac surgery
Myocarditis
Cardiotoxic agents, i.e., anthracyclines, Herceptin
Rhabdomyolysis with cardio-involvement
Multi-factorial or Indeterminate Heart failure
Stress (Takotsubo) cardiomyopathy
Massive pulmonary embolism or pulmonary hypertension
Sepsis or critical illness
Acute kidney injury or chronic kidney disease
Severe acute central nervous system disease, i.e., stroke, subarachnoid 
hemorrhage
Infiltrative diseases, i.e., amyloidosis, sarcoidosis
Strenuous exercise
Table 5. Various etiologies of cardiac troponin positivity in myocardial injury [4].
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of several isoforms of troponin depends upon differential 
gene expression in particular tissues. For example, expres-
sion of cTnC occurs in both cardiac and skeletal muscle, mak-
ing it a poor indicator of myocardial injury. In contrast, cTnT 
and cTnI are expressed almost exclusively in myocardial tis-
sue, making them ideal markers of myocardial damage [10]. 
Both cTnT and cTnI possess unique N-terminal amino acid se-
quences, ideal targets for modern serum assays [11], which 
were developed using antibodies directed against these se-
quences [12]. Utilization of these assays to detect cTn positiv-
ity in serum has proven both highly sensitive and specific for 
myocardial injury [13]. Prior to their development, clinical de-
cision-making relied on the detection of other molecular bio-
markers such as CK-MB, lactate dehydrogenase, and myoglo-
bin, which all lacked specificity, due to their expression in the 
musculoskeletal tissue (Table 3) [14]. The various biomarkers 
have different properties, with troponins having the most ide-
al kinetics, along with the highest sensitivity and specificity, 
for acute coronary syndromes (Table 4) [1].
Pathophysiology of Troponin Release
Detection of cTn proteolytic products
Accurate interpretation of cTn positivity can be challenging be-
cause it relies on unverified assumptions, such as the exclu-
sive provenience of cTn from cardiac myocytes, the freedom 
from laboratory error, the appropriate time of acquisition of 
blood samples, and the cognizance of the patient baseline cTn 
values [15]. Based on these postulations, every incremental 
change in cTnT, cTnI, and CK-MB, even the smallest, is seen as 
persuasive evidence for myocardial injury [5,6,15,16]. However, 
such a dogma seems to be challenged by a fresher revisita-
tion of old findings. It is known that elevated cTn levels can 
reflect not only the detection of intact cTn, but also of its pro-
teolytic degradation products, generated by the calcium-acti-
vated protease, calpain. Such products, due to their reduced 
size, may egress from cells more easily and rapidly than their 
parent structural proteins. Calpain activation, eventuating in 
generation of proteolytic products, may explain the apparent 
inconsistency of modest, persistent elevations of cTn associ-
ated with negative CK-MB, which can occur in some patients 
suffering from recurrent bouts of short-lasting sublethal myo-
cardial ischemia, or in the setting of systemic inflammatory 
processes [15]. Furthermore, recent findings indicate that car-
diac troponin T (cTnT) is also expressed in human smooth mus-
cle cells of different organs and apparatuses, including aorta, 
trachea, gut, and urinary bladder [17]. Hence, calpain activa-
tion at these sites would result, at least theoretically, in mild 
troponinemia (i.e., a slight troponin increase), which is totally 
unrelated to myocardial ischemia or any other cardiac injury.
Detection of intact cTn
Disruption of myocyte cell membrane integrity (occurring in 
any type of myocardial injury) results in leakage of cytoplas-
mic proteins into the extracellular serum. The majority of cTn 
is bound to actin thin filaments; however, a small proportion 
of approximately 3–8% exists in an unbound state, free in 
the cytosol [18]. During myocardial injury, this unbound tro-
ponin is released first and detected as the initial rise of tro-
ponin assays [19]. Troponin elevations from this pool, in cases 
of short-lasting myocardial ischemia or injury, would be ex-
pected to quickly rise and fall over the course of hours due to 
the relatively short half-life (2–4 hours) of cTnI and cTnT [20]. 
However, if there is significant injury causing extensive and pro-
gressive necrosis, a continued release of the myofibril-bound 
troponin pool results in elevations of cTnI and cTnT for up to 
7–14 days. From a pathophysiological standpoint, release of 
cTn into the circulation can be caused by 2 major categories of 
events: 1) myocardial injury due to ischemia (including ACS), 
and 2) myocardial injury in the absence of ischemia.
Ischemic myocardial injury
The majority of ischemic myocardial injury is caused by ob-
structive coronary artery disease, which may result in ACS. 
Ischemia, defined as reduced oxygen availability due to lack 
of blood flow, causes a series of crucial biochemical and met-
abolic changes, which decrease mitochondrial oxidative phos-
phorylation and deplete cellular adenosine triphosphate (ATP). 
If ischemia is prolonged, metabolism shifts to anaerobic gly-
colysis with lactate accumulation and consequent intracellu-
lar acidosis, which activates the Na+-H+ exchanger. The ensu-




Myosin binding sites become exposed once calcium binds to troponin complex




Figure 2.  Physiology of contraction-relaxation cycle in cardiac 
myocytes and role of troponin [10].
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causes accumulation of cytosolic Na+, which is exchanged with 
Ca2+ from the sarcoplasmic reticulum, resulting in overload of 
intracellular Ca2+ [21]. Such alterations in cellular metabolism 
lead to osmotic cell stress, lysosomal activation, reactive oxy-
gen species production, and infiltration of inflammatory cells, 
which actively release mediators, promoting both inflamma-
tion and increased catabolism [22]. Accordingly, the metabol-
ic state arising from ischemic myocardial injury results in cat-
abolic protein degradation and compromised cell membrane 
integrity, allowing for leakage of cytoplasmic proteins into the 
extracellular serum, and subsequent detection of cTn on se-
rum assays.
Clinical encounters associated with ischemic myocardial 
injury
Besides obstructive CAD and ACS, typically occurring in the 
setting of thrombotic coronary artery obstruction, elevation of 
cTn may be caused by a number of other disease states that 
do not compromise coronary artery patency. Elevation of cTn 
in the absence of obstructive CAD is often caused by ischemia 
secondary to an imbalance between demand and supply for 
oxygen-rich blood flow (demand ischemia). Thus, in the 2018 
Joint ESC/ACCF/AHA/WHF Fourth Universal Definition of MI, 
demand ischemia is referred to as type-2 myocardial infarc-
tion, which is cardiac ischemia due to either increased oxygen 
demand or decreased supply, occurring in the absence of an 
acute primary coronary thrombotic event [4]. The conditions 
leading to demand ischemia are very broad and diverse. The 
most commonly observed disorders in clinical practice include 
fixed coronary artery atherosclerosis, coronary spasm, coronary 
embolism caused by thrombi, calcium, or vegetation originat-
ed from atria or ventricles, coronary artery dissection with or 
without intracoronary hematoma, tachyarrhythmias, bradyar-
rhythmias, severe hypertension with or without left ventricu-
lar hypertrophy, hypovolemic shock and other types of hypo-
tension, and severe anemia (Table 5).
Myocardial injury in the absence of ischemia
Numerous clinical conditions other than ACS and ischemic 
myocardial injury have been recognized to cause elevated 
cTn, with several occurring independent of myocardial ne-
crosis [23–25]. Different mechanisms for troponin release in 
non-ACS disorders have been postulated, including, but not 
limited to, increased cell membrane permeability due to re-
versible injury or myocardial stretch [26] and increased rates 
of cell turnover, whether physiologic or pathologic [27]. Such 
mechanisms seem to have a common denominator in the hy-
percatabolic state associated with the generation of inflam-
matory and/or hormonal catabolic molecules.
Indeed, it is well known that inflammatory molecules, like those 
produced from reperfusion injury, can cause the formation of 
reactive oxygen species (ROS) via altered mitochondrial oxi-
dation and function. ROS interact with cell membrane phos-
pholipids, which alters membrane permeability and favors the 
extracellular leakage of cytosolic proteins [28]. Cell membrane 
dysfunction also causes cytosolic Ca+ overload, which is partic-
ularly important because Ca2+ activates specific proteases able 
to reinforce myofibril degradation [28,29]. Moreover, levels of 
circulating catecholamines and inflammatory cytokines, like 
tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1), 
and interleukin-6 (IL-6), are known to increase in catabolic 
conditions such as sepsis, immunological diseases, trauma, 
and/or chronic diseases. It was recently postulated that such 
molecules stimulate muscular fiber proteolysis, most notably 
in skeletal muscle, but also in cardiac myocytes, contributing 
to the hypercatabolic state [30]. Furthermore, animal studies 
showed that IL-6, TNF-alpha, and circulating catabolic mole-
cules bind specific cardiomyocyte membrane receptors, engag-
ing an intracellular cascade (likely via the phosphatidylinositol 
(PI3K)/Aky pathway), whose activation results in protein disar-
rangement. Protein Kinase B (or Ak strain transforming/AKT), 
a key molecule in such a pathway, decreases the phosphory-
lation (and therefore the activity level) of mammalian target 
of rapamycin (mTOR), which exerts pro-catabolic effects by in-
hibiting the synthesis of survival proteins such as eukaryotic 
initiation factor binding protein-1 (4E-BP1) and S6 ribosomal 
protein, and activating the ubiquitin proteasome system, with 
ensuing intracellular protein breakdown [31]. The adverse ef-
fects of cytokines on cardiac cells and sarcomeres are com-
pounded by other molecular mechanisms responsible for pro-
teolysis and myocyte loss. Indeed, binding of TNF-alpha to its 
membrane receptor results in direct myocyte apoptosis (elic-
ited by activation of the death receptor, caspase 8-mediat-
ed pathway), and activation of other pro-apoptotic molecules 
such as Bcl-2-associated X protein (BAX) [32]. Figure 3 illus-
trates the potential mechanisms of contractile protein break-
down associated with hypercatabolic states.
Clinical encounters of elevated cardiac biomarkers in the 
absence of ischemia
Numerous conditions, varied in presentation and nature, can 
engender myocardial injury in the absence of ischemia. Such 
conditions include: sepsis, cerebrovascular accidents, cardio-
toxic medications, renal failure, infiltrative diseases, acute re-
spiratory failure, extreme exertion, cardiac contusion, burns 
affecting >30% of the body surface area, pacing and electrical 
shock in the setting of cardioversion, carbon monoxide expo-
sure, Takotsubo cardiomyopathy, peripartum cardiomyopathy, 
heart failure, endocarditis, myocarditis, myopericarditis, rhab-
domyolysis, and sequelae of malignancy. Among these, the 
most studied are sepsis, neurogenic diseases such as stroke 
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and subarachnoid hemorrhage, and cardiotoxic medications 
such as anthracyclines and trastuzumab.
Sepsis-induced cardiomyopathy
Despite major advances in an organized treatment approach to 
sepsis over the last 2 decades, sepsis remains the most com-
mon cause of death in critically ill patients [33]. Sepsis-induced 
cardiomyopathy is a common complication of sepsis, defined 
by left ventricular dilation with normal or low filling pressures, 
a decrease in LVEF, and normalization of cardiac function, typi-
cally within 7–10 days [34]. However, sepsis-induced cardiomy-
opathy has also been described in the setting of normal LVEF 
due to complex hemodynamic changes during sepsis, includ-
ing decreased systemic vascular resistance, tachycardia, and 
significant alterations in intravascular volume during resusci-
tation [35]. Septic cardiomyopathy commonly results in ele-
vated serum levels of cardiac troponin, which has significant 
prognostic value. The pathophysiologic mechanisms underly-
ing septic cardiomyopathy involve the release of cardiac-de-
pressive factors like endotoxin and endogenous inflammatory 
cytokines (TNF-alpha, IL-1, and IL-6), thereby increasing nitric 
oxide production. Excess nitric oxide depresses myofibril re-
sponse to calcium, downregulates beta-adrenergic receptors, 
and leads to global mitochondrial dysfunction [34]. These cel-
lular alterations cause protein demolition, impair the contrac-
tile apparatus, and increase the microvascular permeability of 
cardiac myocytes [35,36], which can facilitate muscle contrac-
tile protein breakdown and troponin release. Inflammatory cy-
tokines like TNF-alpha, IL-1, and IL-6 have been shown to cause 
degradation of proteins, including free troponin, to lower mo-
lecular-weight fragments, which are released into systemic 
circulation through the highly permeable membranes of car-
diac myocytes [30]. The detection of these small troponin frag-
ments by conventional assays would explain troponinemia in 
the absence of myocyte necrosis. Although this hypothesis is 
highly contentious and not supported by definitive evidence, 
the clinical observation that sepsis-related myocardial depres-
sion resolves without residual ventricular wall motion abnor-
malities [34] suggests that cardiac enzymes can be released in 
the absence of significant cardiomyocyte cell death.
Septic cardiomyopathy is commonly accompanied by an ele-
vation of serum cTn, which is highly correlated with left ven-
tricular dysfunction and increased mortality [34,35,37–39]. In 
one study of 58 consecutive patients admitted to the medical 
intensive care unit with sepsis, all patients with LVEF <45% 
had detectable serum levels of cardiac troponin. The degree 
of troponin elevation demonstrated a significant inverse cor-
relation with LVEF, and 30-day mortality was 4 times great-
er in patients with elevated troponin levels [38]. Regardless 
of the mechanism of troponin leakage, septic cardiomyopa-
thy demonstrates that elevated serum troponin, especially in 
critically ill patients, should not be assumed to indicate ACS or 
the presence of obstructive coronary artery disease. Critically 
ill patients often have multiple non-coronary etiologies of se-
rum cTn elevation, which may be deceivingly heightened or 
prolonged by concomitant renal impairment. Unfortunately, 
no specific treatment exists for septic cardiomyopathy except 
for implementing evidence-based, guideline-directed therapy 
for the treatment of sepsis [35]. While it is not recommended 
by guideline-directed therapy, physicians may utilize cardiac 
enzymes as an adjunctive tool to risk-stratify septic patients 
in the intensive care unit in an effort to optimize treatment 
strategies and improve outcomes.
Neurogenic cardiac damage
An elevation of cTn, often associated with electrocardiogram 
abnormalities and clinical evidence of left ventricular dysfunc-
tion, is detected in up to 20% of patients after stroke, particu-
















protein chain (e.g. cTnl)
relase
Figure 3.  Postulated biochemical mechanisms 
responsible for hypercatabolic protein 
breakdown.
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another postulated mechanism for cardiac damage in this spe-
cific patient population seems to be myocardial injury elicited 
by centrally mediated release of catabolic molecules like cate-
cholamines in response to hypoperfusion of the posterior hy-
pothalamus. A powerful catecholamine surge may be an alter-
native mechanism of cardiac damage, because troponinemia 
is often detected even in young individuals with very low pre-
test probability for an acute coronary syndrome. Cardiac myo-
fibrillar degeneration, which was described in patients who 
died due to acute stroke, occurs in the proximity of the cardi-
ac nerves and is histologically indistinguishable from myocyte 
death caused by catecholamine infusion or reperfusion of tran-
siently ischemic myocardium [41], being characterized by con-
traction bands necrosis and associated with mononuclear infil-
tration and early calcification. Mounting evidence suggests that 
stroke affecting the insular cortex, which plays a central role 
in the autonomic control of cardiovascular function, is associ-
ated with increased risk of adverse cardiac outcomes, includ-
ing neurogenic cardiac damage. Brain regions associated with 
cTnT elevation include the right posterior, superior, and medi-
al insula, and the right inferior parietal lobule.
Medication-induced troponin release
Many medications, especially chemotherapeutics and anti-
neoplastic agents, have adverse effects on cardiac myocytes 
and contribute to the development of cardiovascular compli-
cations such as hypertension, heart failure, arrhythmias, and 
ischemia, all of which may be accompanied by elevated serum 
cardiac biomarkers [42]. Advances in cancer treatment provide 
a unique opportunity for cardiologists and oncologists to col-
laborate in an effort to improve treatment outcomes for pa-
tients with concomitant heart disease and malignancy [43]. 
One way to mitigate the cardiovascular complications of can-
cer treatment is to expand the current guidelines regarding 
cardiac monitoring during the administration of cardiotoxic 
chemotherapeutic agents. Besides cardiac imaging, physicians 
have also discussed the routine monitoring of serum cardiac 
troponin before and during treatment with cardiotoxic med-
ications, in an effort to diagnose cardiotoxicity at its earliest 
stages, when it is more amenable to medical treatment [44].
While a comprehensive review of cardiotoxic medications is 
beyond the scope of this discussion, Table 6 reports some of 
the medications commonly implicated in the causality of car-
diac damage. A brief review of the most studied cardiotoxic 
medications is presented below.
Anthracyclines injure cardiac myocytes primarily by inhib-
iting topoisomerase 2-beta, which increases breaks in dou-
ble-stranded DNA [45] in addition to increasing free radical 
production via iron deposition in mitochondria [46]. These 
mechanisms can lead to apoptosis, necrosis, and permanent 
cardiomyopathy [45,46]. Anthracyclines also increase intra-
cellular calcium levels and cause direct cellular injury through 
drug metabolism, oxidative damage, and influx of pro-inflam-
matory molecules. A direct correlation exists between the cu-
mulative dose of anthracycline, the magnitude of troponin 
elevation, and the subsequent degree of left ventricular dys-
function, which is often permanent [47].
Trastuzumab is a monoclonal antibody that antagonizes the 
human epidermal growth factor receptor 2 (HER-2), which is 
expressed in 20–25% of breast cancers. It has reduced disease 
recurrence and increased survival in patients with breast can-
cers that express HER-2, especially when it is combined with 
anthracyclines like doxorubicin [48]. Unfortunately, this com-
bination results in cardiac dysfunction in approximately 25% 
of patients [49]. Anthracycline-induced oxidative damage to 
cardiomyocytes results in upregulation of HER-2 receptors as 
part of cellular repair. While trastuzumab inhibition of HER-
2-mediated cell repair plays a role in the loss of cardiac my-
ocytes, the precise mechanism of trastuzumab-induced car-
diomyopathy is still unclear [49]. Such cardiomyopathy differs 
from that caused by anthracyclines in that the cardiac dys-
function is not dose-dependent, and it is reversible in approx-
imately 60% of patients [50]. Elevated cardiac biomarkers in 
the setting of trastuzumab regimen decrease the chance of 
cardiac recovery and increase the risk for major adverse car-
diac events (MACE) [50]. Patients with elevated troponin who 
were treated with trastuzumab had a greater risk of develop-
ing cardiac dysfunction and a 25-fold increase in MACE [49]. 
Patients at highest risk were those treated with both anthra-
cyclines and trastuzumab [51], requiring cardiac monitoring 
with serial echocardiograms or multigated acquisition scans 
(MUGA), due to the risk of cardiac injury and left ventricular 
dysfunction. High-sensitivity cTn measured prior to and dur-
ing the administration of trastuzumab seems to be useful in 
the early identification of patients at higher risk of developing 
drug-induced cardiotoxicity, as well as of those whose cardi-
ac function will remain impaired despite an appropriate med-
ical regimen [50].
While anthracyclines and trastuzumab are the most stud-
ied cardiotoxic medications used in cancer treatment, a host 
of anti-neoplastic agents are known to produce cardiac dys-
function and have the potential to cause an elevation of car-
diac biomarkers. The major classes of anti-neoplastic agents 
most commonly associated with troponin elevations are list-
ed in Table 6. As the field of oncology continues to advance, 
more malignancies are being managed with a variety of nov-
el therapeutics. The evaluation of cardiac biomarkers before 
and during cancer treatment, in conjunction with serial imag-
ing studies, is currently the earliest and most accurate way to 
identify cardiotoxicity, and has the potential to be integrated 
into future cardio-oncology guidelines.
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Conclusions
In this review, we described the different pathophysiological 
mechanisms of cTn release, and appraised a variety of clinical 
conditions presenting with elevated cTn, giving special attention 
to those cases of troponinemia unrelated to obstructive CAD.
Ischemic myocardial injury is most commonly caused by ob-
structive coronary artery disease and ACS, which typically oc-
cur in the setting of thrombotic coronary artery occlusion. The 
2018 Joint ESC/ACCF/AHA/WHF Fourth Universal Definition 
of MI placed greater emphasis on the measurement of cardi-
ac enzymes, specifically high-sensitivity cTn, in the diagnos-
tic criteria of acute myocardial infarction [4]. Testing of car-
diac enzymes is ordered in 16.9% of patients presenting to 
emergency departments in the United States, but chest pain 
only accounts for approximately 5.3% of chief complaints [52]. 
Current international guidelines regarding chest pain recom-
mend trending serial cTn and EKGs to assess for a potentially 
evolving ACS, thereby subjecting many patients to prolonged ED 
observation or hospital admission, and increasing the number 
of false-positive troponin results in patients with low pretest 
probability for coronary artery disease [53–55].
The term myocardial infarction in the absence of obstructive 
coronary artery disease (MINOCA) is an increasingly recognized 
diagnosis used to describe ischemic myocardial injury resulting 
in elevated cTn, despite insignificant coronary artery disease 
on angiography [56]. Mild troponinemia can also reflect the de-
tection of small proteolytic products of cTn, which are released 
in the circulation following calpain activation in the setting of 
recurrent bouts of short-lasting sublethal myocardial ischemia 
or systemic inflammatory processes [16]. Likewise, calpain ac-
tivation in organs other than the heart (such as smooth mus-
cle cells of the aorta, trachea, gut, and urinary bladder, where 
cTnT is also expressed) might explain the occurrence of tro-
poninemia in medical conditions totally unrelated to myocar-
dial ischemia or any cardiac injury.
Scoring systems incorporating the first cTn, such as a low 
HEART score (0–3) or low TIMI score (0–1), are the most helpful 
















Proteasome inhibitors Carfilzomib and bortezomib




Table 6. List of cardiotoxic medications [42,43,47].
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with a low pretest probability for ACS, an elevation in cardi-
ac biomarkers can become a confounding factor, delaying the 
formulation of the correct diagnosis and thereby postponing 
initiation of adequate medical management.
Regardless of the clinical situation, elevated serum tropo-
nin is associated with increased mortality and adverse out-
comes [58–60], and may be used to risk-stratify patients. 
Awareness of the multiple conditions associated with positive 
troponin, as well as understanding of the pathophysiology of 
its release, are essential preconditions for minimizing unnec-
essary, costly, and potentially risky interventions, providing 
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